Identification of MiR-145 and MiR-146a As Mediators of the 5q- Syndrome Phenotype

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2009 Nov 10

PMID 19898489

Citations 326

Authors

Daniel T Starczynowski

Florian Kuchenbauer

Bob Argiropoulos

Sandy Sung

Ryan Morin

Andrew Muranyi

Martin Hirst

Donna Hogge

Marco Marra

Richard A Wells

Rena Buckstein

Wan Lam

R Keith Humphries

Aly Karsan

Affiliations

Soon will be listed here.

Abstract

5q- syndrome is a subtype of myelodysplastic syndrome characterized by severe anemia and variable neutropenia but normal or high platelet counts with dysplastic megakaryocytes. We examined expression of microRNAs (miRNAs) encoded on chromosome 5q as a possible cause of haploinsufficiency. We show that deletion of chromosome 5q correlates with loss of two miRNAs that are abundant in hematopoietic stem/progenitor cells (HSPCs), miR-145 and miR-146a, and we identify Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP) and tumor necrosis factor receptor-associated factor-6 (TRAF6) as respective targets of these miRNAs. TIRAP is known to lie upstream of TRAF6 in innate immune signaling. Knockdown of miR-145 and miR-146a together or enforced expression of TRAF6 in mouse HSPCs resulted in thrombocytosis, mild neutropenia and megakaryocytic dysplasia. A subset of mice transplanted with TRAF6-expressing marrow progressed either to marrow failure or acute myeloid leukemia. Thus, inappropriate activation of innate immune signals in HSPCs phenocopies several clinical features of 5q- syndrome.

Citing Articles

Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.

Gharaee N, Wegrzyn-Woltosz J, Jiang J, Akhade V, Bridgers J, Stubbins R Leukemia. 2025; .

PMID: 40000845 DOI: 10.1038/s41375-025-02537-2.

Genome sequencing in the management of myelodysplastic syndromes and related disorders.

Cazzola M, Malcovati L Haematologica. 2024; 110(2):312-329.

PMID: 39445412 PMC: 11788631. DOI: 10.3324/haematol.2023.284947.

Pathogenesis and inflammaging in myelodysplastic syndrome.

Villaume M, Savona M Haematologica. 2024; 110(2):283-299.

PMID: 39445405 PMC: 11788632. DOI: 10.3324/haematol.2023.284944.

Immune-dysregulation harnessing in myeloid neoplasms.

Sharifi M, Xu L, Nasiri N, Ashja-Arvan M, Soleimanzadeh H, Ganjalikhani-Hakemi M Cancer Med. 2024; 13(17):e70152.

PMID: 39254117 PMC: 11386321. DOI: 10.1002/cam4.70152.

MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response.

Micheva I, Atanasova S Front Oncol. 2024; 14:1410656.

PMID: 39156702 PMC: 11327013. DOI: 10.3389/fonc.2024.1410656.

References

Garzon R, Volinia S, Liu C, Fernandez-Cymering C, Palumbo T, Pichiorri F . MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6):3183-9. PMC: 2265455. DOI: 10.1182/blood-2007-07-098749. View

Lamothe B, Besse A, Campos A, Webster W, Wu H, Darnay B . Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem. 2006; 282(6):4102-12. PMC: 3221607. DOI: 10.1074/jbc.M609503200. View

Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C . Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood. 2004; 103(11):4285-93. DOI: 10.1182/blood-2003-09-3192. View

Nagai Y, Garrett K, Ohta S, Bahrun U, Kouro T, Akira S . Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 2006; 24(6):801-812. PMC: 1626529. DOI: 10.1016/j.immuni.2006.04.008. View

Tang M, Wei X, Guo Y, Breslin P, Zhang S, Zhang S . TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J Exp Med. 2008; 205(7):1611-9. PMC: 2442639. DOI: 10.1084/jem.20080297. View

Corral L, Haslett P, Muller G, Chen R, Wong L, Ocampo C . Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999; 163(1):380-6. View

Nilsson L, Eden P, Olsson E, Mansson R, Astrand-Grundstrom I, Strombeck B . The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood. 2007; 110(8):3005-14. DOI: 10.1182/blood-2007-03-079368. View

Nimer S . Myelodysplastic syndromes. Blood. 2008; 111(10):4841-51. DOI: 10.1182/blood-2007-08-078139. View

Bigoni R, Cuneo A, Milani R, Cavazzini F, Bardi A, Roberti M . Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. Haematologica. 2001; 86(4):375-81. View

10.

Li X, Bryant C, Deeg H . Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol. 2004; 80(2):140-5. DOI: 10.1532/ijh97.na0402. View

11.

Corey S, Minden M, Barber D, Kantarjian H, Wang J, Schimmer A . Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007; 7(2):118-29. DOI: 10.1038/nrc2047. View

12.

Boultwood J, Fidler C, Strickson A, Watkins F, Gama S, Kearney L . Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002; 99(12):4638-41. DOI: 10.1182/blood.v99.12.4638. View

13.

Chen H, Li M, Campbell R, Burkhardt K, Zhu D, Li S . Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene. 2006; 25(49):6520-7. DOI: 10.1038/sj.onc.1209653. View

14.

Martinez-Ramirez A, Urioste M, Melchor L, Blesa D, Valle L, de Andres S . Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array. Genes Chromosomes Cancer. 2004; 42(3):287-98. DOI: 10.1002/gcc.20154. View

15.

Starczynowski D, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A . High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood. 2008; 112(8):3412-24. DOI: 10.1182/blood-2007-11-122028. View

16.

Takada S, Yamashita Y, Berezikov E, Hatanaka H, Fujiwara S, Kurashina K . MicroRNA expression profiles of human leukemias. Leukemia. 2007; 22(6):1274-8. DOI: 10.1038/sj.leu.2405031. View

17.

Mansell A, Brint E, Gould J, ONeill L, Hertzog P . Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4. J Biol Chem. 2004; 279(36):37227-30. DOI: 10.1074/jbc.C400289200. View

18.

Li Z, Lu J, Sun M, Mi S, Zhang H, Luo R . Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008; 105(40):15535-40. PMC: 2563085. DOI: 10.1073/pnas.0808266105. View

19.

Hast R, Eriksson M, Widell S, Arvidsson I, Bemell P . Neutrophil dysplasia is not a specific feature of the abnormal chromosomal clone in myelodysplastic syndromes. Leuk Res. 1999; 23(6):579-84. DOI: 10.1016/s0145-2126(99)00042-9. View

20.

Bhaumik D, Scott G, Schokrpur S, Patil C, Campisi J, Benz C . Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008; 27(42):5643-7. PMC: 2811234. DOI: 10.1038/onc.2008.171. View